About this webinar
Cell Guidance Systems is delighted to be joined by Dr Petr Baranov from Harvard Medical School in a live webinar.
Abstract: Blindness and vision impairment resulting from a loss or diminishment of retinal ganglion cells (RGCs) are irreversible. While the underlying pathology (elevation of intraocular pressure, acute trauma, poisoning, ischemia, inflammation as well as mutations in genomic and mitochondrial DNA) is diverse, all optic neuropathies (ON) phenotypically resemble neurodegenerative disease. From an initial decrease in the visual field patients gradually progress towards a complete loss of vision. Recent progress within the field of axon regeneration and RGC transplantation experiments demonstrated the feasibility of RGC cell replacement as a therapeutic approach. Our group works on the early critical aspects of cell replacement therapy: scale-up RGC differentiation and isolation from iPS/ES cell lines and the ability to subsequently transplant those in-vitro manufactured RGCs into the mouse models of RGC loss. Here I am going to discuss the utility of growth factor slow-release systems as a tool to improve neuron maintenance in-vitro.
Cell Guidance Systems' reagents and services enable control, manipulation and monitoring of the cell, both in-vitro and in-vivo.
Share this webinar